Supira Medical, Inc., a Shifamed Portfolio Company, Receives FDA Breakthrough Device Designation as the Company Closed $40M in Series D Financing

Los Gatos, Calif., November 21, 2023 - Supira Medical, Inc., a Shifamed portfolio company, announced today that it has received U.S. Food and Drug Administration (FDA) breakthrough device designation for its Supira System, a next-generation percutaneous ventricular assist device (pVAD). This approval comes as the company closed $40M in Series D financing and prepares to initiate its U.S. clinical program.

Read More

Supira Medical, Inc., a Shifamed Portfolio Company, Receives FDA Breakthrough Device Designation as the Company Closed $40M in Series D Financing2023-11-21T08:47:46-08:00

Supira Medical’s Next Generation Percutaneous Ventricular Assist Device (pVAD) System to be Highlighted in a Live Case and Multiple Sessions at the Upcoming TCT 2023 Conference

Supira’s technology features a novel low profile, high continuous flow design that aims to provide full hemodynamic support for high-risk percutaneous coronary interventions (HRPCI) and cardiogenic shock (CS) patients with a single device

Los Gatos, Calif.,  October 20, 2023 - Supira Medical, Inc., a Shifamed portfolio company, announced today that the company’s percutaneous ventricular assist device (pVAD) will be showcased in multiple sessions, including a live case presentation, during the 2023 Transcatheter Cardiovascular Therapeutics (TCT) conference taking place October 23-26 in San Francisco, CA.

Read More

Supira Medical’s Next Generation Percutaneous Ventricular Assist Device (pVAD) System to be Highlighted in a Live Case and Multiple Sessions at the Upcoming TCT 2023 Conference2023-11-21T08:47:59-08:00

Supira Medical’s Percutaneous Ventricular Assist Device (pVAD) to be Highlighted During PCR Innovator’s Day and SCAI 2023

Supira’s technology features a novel low profile, high continuous flow design that aims to provide full hemodynamic support for high-risk percutaneous coronary interventions (HRPCI) and cardiogenic shock (CS) patients with a single device. Data from the Company’s First-in-Human trial to be presented as part of the Late-Breaking Clinical Research Session at SCAI 2023

Los Gatos, Calif., May 12, 2023 – Supira Medical, Inc., a Shifamed portfolio company, announced today that its next generation percutaneous ventricular assist device (pVAD) was selected following a highly competitive review process to be highlighted as part of this year’s European Association of Percutaneous Cardiovascular Interventions conference (EuroPCR) Innovator’s Day in Paris, France. Gagan Singh M.D., M.S., Director of Clinical Cardiovascular Research at University of California, Davis, will present on behalf of the company during the “Innovations in Heart Failure: Pumps, Remodeling and Monitoring” session beginning at 12:05 pm CET on Monday, May 15th in the Theatre Havane of the Palais de Congrès. Additionally, Supira Medical will be at booth M23 where PCR attendees can learn more about the system.

Read More

Supira Medical’s Percutaneous Ventricular Assist Device (pVAD) to be Highlighted During PCR Innovator’s Day and SCAI 20232023-05-12T11:02:28-07:00

Supira Medical Announces Successful First-In-Human Use Of Its Next Generation Percutaneous Ventricular Assist Device

Three leading U.S. interventional cardiologists attend initial cases as company prepares to expand its clinical program

Los Gatos, Calif., September 16, 2022 – Supira Medical, Inc., a Shifamed portfolio company focused on developing the next-generation solution for mechanical circulatory support, announced today it has initiated its first-in-human clinical study performed by principal investigator, Adrian Ebner, M.D., Head of the Cardiovascular Department at the Italian Hospital Asuncion Paraguay. The prospective, single-arm, single-center study will evaluate the safety and performance of Supira’s low-profile, high-flow percutaneous ventricular assist device (pVAD) to support cardiovascular hemodynamics in patients undergoing high-risk percutaneous coronary interventions (HRPCI).

Read More

Supira Medical Announces Successful First-In-Human Use Of Its Next Generation Percutaneous Ventricular Assist Device2022-09-15T15:43:10-07:00

Supira Medical, A Shifamed Portfolio Company, Closes $30m in an Oversubscribed Series C Financing

Company to Advance its Next Generation Percutaneous Ventricular Assist Device

Los Gatos, Calif., February 28, 2022 – Supira Medical, Inc., a Shifamed portfolio company that is focused on developing a next-generation solution for temporary mechanical circulatory support, announced today the closing of $30M in Series C financing. Led by Cormorant Asset Management and The Capital Partnership (TCP), with participation from 415 CAPITAL, AMED Ventures, PA MedTech VC Fund and Shifamed angel investors, the funds will be used to finalize product development and initiate a first-in-human clinical study for the company’s high-flow, low-profile percutaneous ventricular assist device (pVAD).

Read More

Supira Medical, A Shifamed Portfolio Company, Closes $30m in an Oversubscribed Series C Financing2022-02-25T15:55:43-08:00

Supira Medical, A Shifamed Portfolio Company, Closes $35M in Series B Financing

Company Appoints Seasoned Medtech Executive as President and CEO

CAMPBELL, Calif., March 5, 2020 – Supira Medical, formed by Shifamed as part of its medical innovation hub, announced today the closing of $35M in Series B financing. Officially closed on February 25, the financing was led by Cormorant Asset Management with participation from The Capital Partnership (TCP), 415 CAPITAL, AMED Ventures and Shifamed Angels. The funds will be used to advance product development and clinical efforts for the company’s next generation percutaneous ventricular assist device (pVAD). Additionally, the company announced the appointment of seasoned medical device executive, Dr. Nitin Salunke, as President and Chief Executive Officer.

Read More

Supira Medical, A Shifamed Portfolio Company, Closes $35M in Series B Financing2020-04-17T11:43:44-07:00
Go to Top